4-Amino-6-methoxy-2-methyloxan-3-ol | 34598-18-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Amino-6-methoxy-2-methyloxan-3-ol
• CAS: 34598-18-0
• 化学式: C₇H₁₅NO₃
• 分子量: 161.201
• InChiKey: UIWJWFKPPXKEJV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same
  申请人：Koch H. Tad

  公开号：US20070275911A1

  公开（公告）日：2007-11-29

  The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.

  本发明提供了一种前药平台技术，通过改变和改进药物特性，如水溶性、水解稳定性、治疗指数、毒性谱、药代动力学和选择性，从而提高各种原始药物化合物的治疗价值，同时允许潜在的合成扩展。该前药平台特别适用于将治疗药物，包括抗肿瘤药物和抗生素，定向靶向到目标细胞（例如癌细胞和细菌）上的特定受体。该平台是一种提供改进的、预激活形式的治疗药物的技术，并可选择性地将该药物定向到目标细胞或生物分子。本发明广泛适用于许多不同的治疗药物，以及多种癌症和细菌感染等不同疾病和病况。
• THERAPEUTIC POLYESTERS AND POLYAMIDES
  申请人：Uhrich Kathryn E.

  公开号：US20080233078A1

  公开（公告）日：2008-09-25

  Polymers (i.e. polyesters, polyamides, and polythioesters or a mixture thereof) which degrade hydrolytically into biologically active compounds are provided. Methods of producing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to deliver biologically active compounds to a host are also provided.
• DETECTION OF OVARIAN CANCER
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US20130078319A1

  公开（公告）日：2013-03-28

  Among other things, the present disclosure provides a method including the steps of: obtaining a uterine sample; and detecting and/or characterizing in the uterine sample an ovarian cancer biomarker (e.g., CA125).
• [EN] PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY<br/>[FR] MATÉRIAUX PÉRITUMORAUX ET INTRATUMORAUX POUR TRAITEMENT ANTICANCÉREUX
  申请人：HARVARD COLLEGE

  公开号：WO2016123573A1

  公开（公告）日：2016-08-04

  The invention provides methods and compositions for reducing tumor-mediated immune evasion and inducing patient-specific immunization.
• [EN] BIOMATERIALS FOR MODULATING IMMUNE RESPONSES<br/>[FR] BIOMATÉRIAUX POUR MODULER DES RÉPONSES IMMUNITAIRES
  申请人：HARVARD COLLEGE

  公开号：WO2018026884A1

  公开（公告）日：2018-02-08

  The provided herein are methods and compositions for eliciting an immune response to an antigen, such as cancer and microbial antigens.